Clearside Biomedical Inc CLSD.OQ CLSD.O is expected to show a rise in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025
The Alpharetta Georgia-based company is expected to report a 88.9% increase in revenue to $170 thousand from $90 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Clearside Biomedical Inc is for a loss of 10 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Clearside Biomedical Inc is $5.00, about 92.3% above its last closing price of $0.38
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.11 | -0.11 | -0.11 | Met | -1.3 |
Dec. 31 2025 | -0.04 | -0.10 | -0.10 | Met | -2.9 |
Sep. 30 2024 | -0.12 | -0.12 | -0.10 | Beat | 19.5 |
Jun. 30 2024 | -0.13 | -0.13 | -0.10 | Beat | 25.9 |
Mar. 31 2024 | -0.14 | -0.14 | -0.15 | Missed | -9 |
Dec. 31 2023 | -0.08 | -0.09 | -0.08 | Beat | 8.6 |
Sep. 30 2023 | -0.16 | -0.15 | -0.15 | Met | 3.2 |
Jun. 30 2023 | -0.14 | -0.14 | -0.15 | Missed | -5.9 |
This summary was machine generated August 8 at 12:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)